Symbols

WW

WW·NASDAQ

--(--)

WW fundamentals

WW Q4 2025 Earnings

WW (WW) released its earnings on Mar 16, 2026: revenue was 162.81M (YoY --), beat estimates; EPS was -0.58 (YoY --), beat estimates.

Revenue / YoY

162.81M

EPS / YoY

-0.58

Report date

Mar 16, 2026

WW Earnings Call Summary for Q4,2025

Clinical Dominance: Med+ ARPU is 4x higher than behavioral, with 100% YoY growth in clinical subscribers (excluding compounded semaglutide). 50% of new Med+ members are brand-new.
Engagement Surge: Virtual workshop attendance up 30% YoY, with physician-led sessions doubling engagement.
2026 Guidance: Revenue $620M-$635M, EBITDA $105M-$115M, driven by clinical expansion and brand repositioning.
GLP-1 Success: Members using GLP-1 Success program lose 29% more weight at 12 months than those on medication alone.

Earnings

EPS

Revenue

Revenue & Expenses

WW has released its 2025 Q4 earnings report, with revenue of 162.81M, reflecting a YoY change of -11.71%, and net profit of -5.83M, showing a YoY change of -123.22%. The Sankey diagram below clearly presents WW's revenue sources and cost distribution.

Key Indicators

WW (WW) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

WW (WW)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

WW (WW)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

WW (WW)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown